IC Targets is the merger of the Norwegian life science companies Epitarget and IC Contrast in 2015. The Company is privately owned by Norwegian private and institutional investors.
The Company repositions the magnetic resonance imaging (MRI) contrast agent mangafodipir for cardiac MRI. The contrast agent allows cardiologists to precisely quantify myocyte viability after heart infarction to guide further treatment. The agent...
IC Targets is the merger of the Norwegian life science companies Epitarget and IC Contrast in 2015. The Company is privately owned by Norwegian private and institutional investors.
The Company repositions the magnetic resonance imaging (MRI) contrast agent mangafodipir for cardiac MRI. The contrast agent allows cardiologists to precisely quantify myocyte viability after heart infarction to guide further treatment. The agent has earlier been marketed for liver imaging with an excellent safety profile. The new indication has been successfully tested in a clinical proof-of-principle study involving 10 patients.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.